Payment overview · 2025
General Payments
$495.99
30 reported records · 10 companies
Healthcare provider profile · identity verified
Hubert Macon Landers, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FORT SMITH, AR · NPI 1538189634
Verified facts
What the public records show
CMS Open Payments records show Hubert Macon Landers, MD received $495.99 in general payments during 2025 across 30 reported records.
Merck Sharp & Dohme LLC accounted for 34.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $170.22 | 34.3% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $108.80 | 21.9% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $72.33 | 14.6% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.83 | 6.8% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$29.98 | 6.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.00 | 4.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.27 | 3.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.42 | 2.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.60 | 2.7% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $13.54 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $495.99 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $170.22 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $108.80 | 6 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $72.33 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.83 | 2 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $29.98 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.60 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 213 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 61 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 93 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 16 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
61 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
213 | 45 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Azithromycin | Azithromycin | 682 | 283 |
| Amlodipine Besylate | Amlodipine Besylate | 674 | 193 |
| Levothyroxine Sodium | Levothyroxine Sodium | 587 | 143 |
| Pantoprazole Sodium | Pantoprazole Sodium | 519 | 140 |
| Atorvastatin Calcium | Atorvastatin Calcium | 469 | 136 |
| Potassium Chloride | Potassium Chloride | 424 | 118 |
| Losartan Potassium | Losartan Potassium | 389 | 108 |
| Gabapentin | Gabapentin | 363 | 81 |
| Omeprazole | Omeprazole | 323 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 322 | 78 |
| Pravastatin Sodium | Pravastatin Sodium | 314 | 88 |
| Furosemide | Furosemide | 295 | 87 |
| Donepezil Hcl | Donepezil Hcl | 273 | 63 |
| Carvedilol | Carvedilol | 270 | 74 |
| Lisinopril | Lisinopril | 270 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 268 | 81 |
| Metformin Hcl | Metformin Hcl | 247 | 64 |
| Baclofen | Baclofen | 223 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 222 | 85 |
| Clopidogrel | Clopidogrel Bisulfate | 220 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 218 | 54 |
| Montelukast Sodium | Montelukast Sodium | 214 | 43 |
| Eliquis | Apixaban | 213 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 213 | 56 |
| Ezetimibe | Ezetimibe | 207 | 57 |
| Allopurinol | Allopurinol | 200 | 56 |
| Amoxicillin | Amoxicillin | 196 | 101 |
| Tamsulosin Hcl | Tamsulosin Hcl | 188 | 52 |
| Trazodone Hcl | Trazodone Hcl | 179 | 52 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 174 | 40 |
| Alendronate Sodium | Alendronate Sodium | 169 | 50 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 160 | 83 |
| Clonidine Hcl | Clonidine Hcl | 160 | 44 |
| Cephalexin | Cephalexin | 158 | 60 |
| Tramadol Hcl | Tramadol Hcl | 158 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 156 | 66 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 141 | 34 |
| Glimepiride | Glimepiride | 138 | 33 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 138 | 31 |
| Fenofibrate | Fenofibrate Nanocrystallized | 137 | 39 |
| Atenolol | Atenolol | 133 | 39 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 133 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 131 | 32 |
| Methylprednisolone | Methylprednisolone | 119 | 83 |
| Torsemide | Torsemide | 114 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 57 |
| Hydralazine Hcl | Hydralazine Hcl | 112 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 15 |
| Terbinafine Hcl | Terbinafine Hcl | 105 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 104 | 34 |
| Alprazolam | Alprazolam | 100 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 29 |
| Sertraline Hcl | Sertraline Hcl | 98 | 24 |
| Nifedipine Er | Nifedipine | 96 | 26 |
| Raloxifene Hcl | Raloxifene Hcl | 94 | 25 |
| Jardiance | Empagliflozin | 93 | 16 |
| Synthroid | Levothyroxine Sodium | 93 | 17 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 92 | 14 |
| Simvastatin | Simvastatin | 92 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 90 | 41 |
| Nitroglycerin | Nitroglycerin | 89 | 47 |
| Memantine Hcl | Memantine Hcl | 87 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 86 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 85 | 23 |
| Valsartan | Valsartan | 80 | 20 |
| Metformin Hcl Er | Metformin Hcl | 79 | 25 |
| Farxiga | Dapagliflozin Propanediol | 77 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 76 | 18 |
| Clonazepam | Clonazepam | 75 | suppressed |
| Klor-Con M20 | Potassium Chloride | 75 | 32 |
| Sucralfate | Sucralfate | 73 | 15 |
| Clonidine | Clonidine | 69 | 14 |
| Irbesartan | Irbesartan | 68 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 67 | 22 |
| Spironolactone | Spironolactone | 62 | 17 |
| Colestipol Hcl | Colestipol Hcl | 61 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 27 |
| Entresto | Sacubitril/Valsartan | 61 | 14 |
| Januvia | Sitagliptin Phosphate | 61 | 12 |
| Lorazepam | Lorazepam | 60 | suppressed |
| Finasteride | Finasteride | 59 | 15 |
| Nystatin | Nystatin | 59 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 57 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 56 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 56 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 54 | suppressed |
| Ranolazine Er | Ranolazine | 54 | 15 |
| Metronidazole | Metronidazole | 51 | 28 |
| Mupirocin | Mupirocin | 51 | 30 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 25 |
| Xarelto | Rivaroxaban | 51 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Bumetanide | Bumetanide | 47 | 11 |
| Warfarin Sodium | Warfarin Sodium | 47 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 46 | suppressed |
| Celecoxib | Celecoxib | 43 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Gemfibrozil | Gemfibrozil | 41 | suppressed |
| Meloxicam | Meloxicam | 41 | 12 |
| Primidone | Primidone | 41 | suppressed |
| Temazepam | Temazepam | 41 | suppressed |
| Fenofibrate | Fenofibrate | 40 | 12 |
| Megestrol Acetate | Megestrol Acetate | 40 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 39 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 38 | 13 |
| Levofloxacin | Levofloxacin | 38 | 23 |
| Prednisone | Prednisone | 38 | 14 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 12 |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 19 |
| Topiramate | Topiramate | 32 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 31 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 29 | suppressed |
| Cefdinir | Cefdinir | 29 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 29 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Metolazone | Metolazone | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Famciclovir | Famciclovir | 25 | suppressed |
| Famotidine | Famotidine | 25 | suppressed |
| Glipizide Er | Glipizide | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 12 |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Minoxidil | Minoxidil | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Trimethoprim | Trimethoprim | 14 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Ozempic | Semaglutide | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $495.99 · 30 records | Merck Sharp & Dohme LLC | COREVALVE EVOLUT R, Cologuard Collection Kit, ELIQUIS, ENTRESTO, EVENITY, JARDIANCE, Kerendia, LEQVIO, LifeVest, NURTEC ODT, VERQUVO, WATCHMAN Access System | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error